# US 11,110,115 B2 · Nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,115 B2
- Document ID: US11110115B2
- Status: Granted
- Kind: B2
- Application number: 16/652,926
- Filed: 2018-10-03
- Published: 2020-08-27
- Granted: 2021-09-07
- Earliest claimed: 2017-10-03
- Assignees: Aptahem AB
- Applicants: Aptahem AB
- Inventors: Luiza Anna Jedlina
- Web page: https://patentgrep.com/patent/US11110115B2

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- C12N 2310/16: Aptamers
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a nucleic acid molecule or a composition comprising said molecule for use as an anti-inflammatory and/or anti-coagulant and/or organ-protective medicament. The invention also relates to a use of said nucleic acid molecule or said composition, for the manufacture of a medicament for preventing, treating, regressing, curing and/or delaying a disease or a condition wherein inflammation and/or coagulation and/or organ damage or failure occurs in an individual. Finally, the invention further relates to a method for alleviating one or more symptom(s) and/or characteristic(s) and/or for improving a parameter of a disease or condition wherein inflammation and/or coagulation and/or organ damage or failure occur in an individual, the method comprising administering to said individual said nucleic acid molecule or said composition.

## Claims

### Claim 1

A method for alleviating one or more symptom(s) and/or characteristic(s) and/or for improving a parameter of a disease or condition wherein inflammation and/or coagulation and/or organ damage or failure occur in an individual, the method comprising administering to said individual an effective amount of a nucleic acid molecule, said nucleic acid molecule comprising the nucleotide sequence set forth as SEQ ID NO:1 or a nucleotide sequence at least 95% identical thereto or comprising the nucleotide sequence set forth as SEQ ID NO:2 or nucleotide sequence at least 95% identical thereto or a pharmaceutical composition comprising said nucleic acid molecule and a pharmaceutically acceptable carrier, adjuvant, salt, diluent and/or excipient.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease or condition wherein inflammation and/or coagulation and/or organ damage or failure occur is selected from acute coronary syndrome (ACS), thrombosis, peripheral vessel obstruction, obstructive arteriosclerosis, vasculitis, functional disorder occurring after heart surgery, complication caused by organ transplantation, angina pectoris, transient ischemic attack, toxemia of pregnancy (preeclampsia, eclampsia), diabetes, liver veno-occlusive disease (VOD), deep venous thrombosis (DVT), sepsis, septic shock, severe sepsis, trauma, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), rheumatoid arthritis (RA), juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease including Crohn's disease or ulcerative colitis, hepatitis, sepsis, alcoholic liver disease, non-alcoholic steatosis, sarcoidosis, autoimmune diabetes, diabetes mellitus, uveitis, multiple sclerosis, Controlling Allograft Rejection after organ transplantation, graft versus host disease (GVHD), inflammatory lung diseases including asthma and chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), sarcoidosis, atopic dermatitis, cancer, infection, poisoning, aspiration syndromes, hypoperfusion or shock, heat-induced illness, ischemia, ischemia-reperfusion injury (IRI), autoimmune disease, hemorrhage, pancreatitis, bacteremia, burns, systemic inflammatory response syndrome (SIRS) and multiple organ failure or multiple organ dysfunction syndrome, or a complication or an effect of the progression that is linked to one of these diseases or conditions.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:1 or comprises the nucleotide sequence set forth as SEQ ID NO:2.

### Claim 4 (depends on 1)

The method according to claim 1, whereby
(a) a parameter associated with inflammation such as the level of a pro-inflammatory cytokine, the level of a pro-inflammatory integrin and/or the number of pro-inflammatory infiltrates is decreased and/or
(b) a parameter associated with coagulation such as fibrin clot formation and/or thrombin concentration is decreased and/or
(c) a parameter associated with organ damage or failure such as AST, ALT, GGT, ALP, LDH, creatine kinase, BUN, albumin, creatinine, glucose, bile acid, total bilirubin, conjugated bilirubin, phosphorus, total protein, LDL cholesterol, HDL cholesterol, cholesterol and/or triglycerides is improved.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecule is single stranded and/or a nucleotide of this nucleic acid molecule is modified compared to a nucleotide present in RNA.

### Claim 6 (depends on 5)

The method according to claim 5, wherein a pyrimidine of the nucleic acid molecule is fluorinated.

### Claim 7 (depends on 6)

The method according to claim 6, wherein all pyrimidines of the nucleic acid molecule are fluorinated.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the individual is administered a pharmaceutical composition comprising said nucleic acid molecule.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecule or pharmaceutical comprising the nucleic acid molecule is intravenously administered to the individual.

### Claim 10

A method for preventing, treating, regressing, curing and/or delaying a disease or a condition wherein inflammation and/or coagulation and/or organ damage or failure occurs the method comprising administering to an individual in need thereof an effective amount of a nucleic acid molecule, said nucleic acid molecule comprising the nucleotide sequence set forth as SEQ ID NO:1 or a nucleotide sequence at least 95% identical thereto or comprising the nucleotide sequence set forth as SEQ ID NO:2 or nucleotide sequence at least 95% identical thereto or a pharmaceutical composition comprising an effective amount of said nucleic acid molecule.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:1 or comprises the nucleotide sequence set forth as SEQ ID NO:2.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the disease or condition wherein inflammation and/or coagulation and/or organ damage or failure occur is selected from acute coronary syndrome (ACS), thrombosis, peripheral vessel obstruction, obstructive arteriosclerosis, vasculitis, functional disorder occurring after heart surgery, complication caused by organ transplantation, angina pectoris, transient ischemic attack, toxemia of pregnancy (preeclampsia, eclampsia), diabetes, liver veno-occlusive disease (VOD), deep venous thrombosis (DVT), sepsis, septic shock, severe sepsis, trauma, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), rheumatoid arthritis (RA), juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease including Crohn's disease or ulcerative colitis, hepatitis, sepsis, alcoholic liver disease, non-alcoholic steatosis, sarcoidosis, autoimmune diabetes, diabetes mellitus, uveitis, multiple sclerosis, Controlling Allograft Rejection after organ transplantation, graft versus host disease (GVHD), inflammatory lung diseases including asthma and chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), sarcoidosis, atopic dermatitis, cancer, infection, poisoning, aspiration syndromes, hypoperfusion or shock, heat-induced illness, ischemia, ischemia-reperfusion injury (IRI), autoimmune disease, hemorrhage, pancreatitis, bacteremia, burns, systemic inflammatory response syndrome (SIRS) and multiple organ failure or multiple organ dysfunction syndrome, or a complication or an effect of the progression that is linked to one of these diseases or conditions.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the nucleic acid molecule or pharmaceutical comprising the nucleic acid molecule is intravenously administered to the individual.

### Claim 14

A method for inhibiting and/or preventing coagulation of the blood in a subject in need thereof, comprising administering to the subject an effective amount of a nucleic acid molecule, said nucleic acid molecule comprising the nucleotide sequence set forth as SEQ ID NO:1 or a nucleotide sequence at least 95% identical thereto or comprising the nucleotide sequence set forth as SEQ ID NO:2 or nucleotide sequence at least 95% identical thereto or a pharmaceutical composition comprising said nucleic acid molecule and a pharmaceutically acceptable carrier, adjuvant, salt, diluent and/or excipient.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:2 or a nucleotide sequence at least 95% identical thereto.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the individual in need thereof is an individual with sepsis.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the nucleic acid molecule or composition comprising the nucleic acid molecule is administered intravenously to the individual.